CA-170
- Generic Name
- CA-170
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CA-170 is a selective, small molecule inhibitor of PD-L1.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02812875
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇰🇷Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath